Status:
COMPLETED
First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation
Lead Sponsor:
AstraZeneca
Conditions:
Pulmonary Cancer
Eligibility:
All Genders
19+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the overall objective tumor response rate (ORR) of Gefitinib.
Eligibility Criteria
Inclusion
- Patients require histological biopsy and paraffin block more than 5mg from the original tumour or metastatic site to perform EGFR mutational analysis
- WHO Performance Status 0-2
- No prior chemotherapy, biological or immunological therapy/surgery
Exclusion
- Any evidence of clinically active interstitial lung disease
- Newly diagnosed CNS metastases that have not yet been definitively treated with surgery /radiation
- Patients with previously diagnosed and treated CNS metastases or spinal cord compression
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT00344773
Start Date
March 1 2006
End Date
December 1 2007
Last Update
June 29 2010
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Seongnam-si, South Korea
2
Research Site
Seoul, South Korea